All > Sclc

Participants With Extensive Small Cell Lung Cancer (All Participants) for Small Cell Lung Cancer

University of Chicago Medicine, Chicago, IL
Small Cell Lung Cancer+2 More ConditionsDurvalumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will explore if combining radiation with durvalumab, carboplatin and etoposide can help treat extensive-stage small cell lung cancer. Participation lasts 48 months.

Eligible Conditions
  • Small Cell Lung Cancer
  • Lung Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Similar Trials

1
Protein Phosphatase 2A Inhibitor LB-100
1
RYZ101 + SoC
1
Bomedemstat

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 48 months

12 months
Progression Free Survival at 12 Months
3 months
Rate of Participants with Grade 3/4 Adverse Events After 3 Months According to the Common Terminology Criteria for Adverse Events
48 months
Overall Survival Rate of Participants After Treatment with Chemotherapy, Durvalumab and Ablative Radiation
Progression-Free Survival of Participant Until Disease Progression or Death
Time to New, Distant Lesions
Time to Second-Line Therapy

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Protein Phosphatase 2A Inhibitor LB-100
1
RYZ101 + SoC
1
Bomedemstat

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

1 Treatment Group

Participants With Extensive Small Cell Lung Cancer (All Participants)
1 of 1

Experimental Treatment

49 Total Participants · 1 Treatment Group

Primary Treatment: Participants With Extensive Small Cell Lung Cancer (All Participants) · No Placebo Group · Phase 2

Participants With Extensive Small Cell Lung Cancer (All Participants)Experimental Group · 4 Interventions: Durvalumab, Etoposide, Carboplatin, Ablative Radiation · Intervention Types: Drug, Drug, Drug, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Durvalumab
FDA approved
Etoposide
FDA approved
Carboplatin
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 months

Who is running the clinical trial?

University of ChicagoLead Sponsor
947 Previous Clinical Trials
759,893 Total Patients Enrolled
Christine Bestvina, MDPrincipal InvestigatorUniversity of Chicago - Comprehensive Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 12 more weeks.
You have cancer that has spread to your brain, but you are not experiencing any symptoms or have been treated for it and are not taking steroids or anti-seizure medication for at least 2 weeks before starting the study.
References

Frequently Asked Questions

Is enrollment for the trial still open?

"As per the information on clinicaltrials.gov, this research is looking for volunteers and has been in operation since August 19th of 2022 with a recent update occurring on February 14th 2023." - Anonymous Online Contributor

Unverified Answer

Has the application for Participants With Extensive Small Cell Lung Cancer (All Participants) been accepted by the FDA?

"Our collective sentiment at Power is that Participants With Extensive Small Cell Lung Cancer (All Participants) have the safety rating of 2, as it has been tested in Phase 2 clinical trials and only preliminary evidence for its efficacy exists." - Anonymous Online Contributor

Unverified Answer

Have any experiments been conducted that included patients diagnosed with extensive small cell lung cancer?

"At present, 1091 clinical trials for Participants With Extensive Small Cell Lung Cancer (All Participants) are live with 293 of those trials in the most advanced phase. Although a number of these studies can be located in Orlando, Florida, there is an expansive network of 58978 research centres researching this disease across the world." - Anonymous Online Contributor

Unverified Answer

What health concerns can be addressed by Participants With Extensive Small Cell Lung Cancer (All Participants)?

"Patients with Extensive Small Cell Lung Cancer (All Participants) often receive this medication to address recurrent cancers. It is also used off-label for advanced cervical cancer, gestational trophoblastic disease and other medical concerns." - Anonymous Online Contributor

Unverified Answer

What is the current enrollment number for this clinical trial?

"Affirmative. Clinicaltrials.gov attests that this research study, which was initially posted on August 19th 2022, is presently recruiting individuals for participation. 49 people are needed to be enrolled from a solitary medical location." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top